Nektar Therapeutics $12.70

up +0.17


23/9/2014 04:00 PM  |  NASDAQ : NKTR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get NKTR Trend Analysis - it has underperformed the S&P 500 by 24%

Partner Headlines

  1. Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting ...

    Benzinga
  2. Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude ...

    Benzinga
  3. Top Healthcare Movers For June 9, 2014

    Benzinga
  4. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga
  5. Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share

    Benzinga
  6. Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common ...

    Benzinga
  7. Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol ...

    Benzinga
  8. Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal ...

    Benzinga
  9. UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected ...

    Benzinga
  10. Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA

    Benzinga
  11. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies ...

    Benzinga
  12. Nektar Reports on Advancements with Clinical Pipeline and Introduces New ...

    Benzinga
  13. Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization ...

    Benzinga
  14. Market Wrap For Friday, September 27: Dow Ends The Week Negative For First ...

    Benzinga
  15. Mid-Afternoon Market Update: Cerner Rallies Major Contract While United ...

    Benzinga
  16. Mid-Day Market Update: Finish Line Gains On Upbeat Results; JC Penney Shares ...

    Benzinga
  17. William Blair Reiterates Outperform Nektar Therapeutics Following NKTR-181 ...

    Benzinga
  18. UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 ...

    Benzinga
  19. Mid-Morning Market Update: Markets Open Lower; BlackBerry Reports Q2 Loss

    Benzinga
  20. Benzinga's Top Pre-Market Losers

    Benzinga
  21. Nektar Says Results from Phase 2 Trial of NKTR-181 Missed Primary Efficacy ...

    Benzinga
  22. Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

    Benzinga
  23. Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains ...

    Benzinga
  24. Mid-Day Market Update: Markets Slump; Facebook Remains Up on Massive Volume

    Benzinga
  25. UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

    Benzinga
  26. Nektar Therapeutics Plunges on FDA Worries, Downgrade

    Benzinga
  27. A Peek Into The Market Before The Trading Starts

    Benzinga
  28. AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal ...

    Benzinga
  29. Stocks Hitting 52-Week Highs

    Benzinga
  30. Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192

    Benzinga
  31. Nektar Therapeutics Reports Operating Results (10-Q)

    GuruFocus
  32. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181

    Benzinga
  33. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181

    Benzinga
  34. Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash

    Benzinga
  35. Morning Social Media Outlook for Thursday Mar 1 (CPRT, NKTR, RIMM, FNSR)

    Benzinga
  36. Nektar Therapeutics (NKTR) Gains 11.5% On Sale of Drug Royalties

    MarketIntelligenceCenter
  37. Nektar Therapeutics Reports Operating Results (10-K)

    GuruFocus
  38. Nektar Therapeutics Up 7% After Selling Royalty Payment Agreements

    Benzinga
  39. UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, ...

    Benzinga
  40. Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII ...

    Benzinga
  41. Notable Call Options Activity on Nektar Therapeutics

    Benzinga
  42. Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor ...

    Benzinga
Trading Center